-
Mashup Score: 0U.S. FDA grants priority review to Roche’s Actemra/RoActemra for the treatment of COVID-19 in hospitalised adults - 2 year(s) ago
If approved, Actemra/RoActemra would be the first U.S. FDA-approved immunomodulator for the treatment of COVID-19 in hospitalised patientsSince the beginning of the pandemic, more than one million…
Source: www.roche.comCategories: Healthcare Professionals, Latest HeadlinesTweet
-
Mashup Score: 1Ad hoc announcement pursuant to Art. 53 LR Roche provides update on phase III SKYSCRAPER-02 study in extensive-stage small cell lung cancer - 2 year(s) ago
Ad hoc announcement pursuant to Art. 53 LR Roche provides update on phase III SKYSCRAPER-02 study in extensive-stage small cell lung cancer SKYSCRAPER-02, the first randomized study of tiragolumab…
Source: www.roche.comCategories: Latest Headlines, UrologyTweet-
JUST IN: RPIII trial of anti-TGIT in small-cell lung cancer did not meet co-primary endpt of PFS. #SKYSCRAPER02. Disappointing news for this new pathway, acknowledging SCLC is a very hard-to-treat disease. More tumor types being investigated. @OncoAlert https://t.co/PrBM4R2KxJ https://t.co/NiY7Rue8ew
-
-
Mashup Score: 66Roche COVID-19 At-Home Test granted FDA Emergency Use Authorization to expand access to rapid self-testing solutions in the United States - 2 year(s) ago
Rapid test to support the American public’s fight against the COVID-19 pandemic, with availability to purchase over-the-counter (OTC) at pharmacies and retailers nationwideThe COVID-19 At-Home Test uses a simple nasal swab sample to enable individuals to self-test at home and receive accurate, reliable and quick results in as few as 20 minutes for SARS-CoV-2 and all known variants of…
Source: www.roche.comCategories: Infectious Disease, Latest HeadlinesTweet-
Great News One of the Worlds largest diagnostics co @Roche finally given FDA EUA to bring its rapid test to US -a test used across the world for a year already EUA happened by NIH stepping in to accelerate FDA. A program I’ve called for for a long time! https://t.co/ECpX58N38p
-
-
Mashup Score: 0Roche COVID-19 At-Home Test granted FDA Emergency Use Authorization to expand access to rapid self-testing solutions in the United States - 2 year(s) ago
Rapid test to support the American public’s fight against the COVID-19 pandemic, with availability to purchase over-the-counter (OTC) at pharmacies and retailers nationwideThe COVID-19 At-Home Test uses a simple nasal swab sample to enable individuals to self-test at home and receive accurate, reliable and quick results in as few as 20 minutes for SARS-CoV-2 and all known variants of…
Source: www.roche.comCategories: Cardiologists, Latest HeadlinesTweet-
.@Roche receives Emergency Use Authorization for its home antigen-based SARS-CoV2 test with sensitivity 95% and specificity 100%. Product of @NIH RADx. Available next month & capable of producing tens of millions per month https://t.co/rkY0vIQa8r
-
-
Mashup Score: 24Roche COVID-19 At-Home Test granted FDA Emergency Use Authorization to expand access to rapid self-testing solutions in the United States - 2 year(s) ago
Rapid test to support the American public’s fight against the COVID-19 pandemic, with availability to purchase over-the-counter (OTC) at pharmacies and retailers nationwideThe COVID-19 At-Home Test uses a simple nasal swab sample to enable individuals to self-test at home and receive accurate, reliable and quick results in as few as 20 minutes for SARS-CoV-2 and all known variants of…
Source: www.roche.comCategories: Healthcare Professionals, Latest HeadlinesTweet-
New at-home rapid antigen test thanks to @NIH funding - not a moment too soon. Merry Christmas! https://t.co/NMPOUnaKHp @US_FDA https://t.co/cZiDqBJNFj
-
-
Mashup Score: 1
Gavreto is the first and only precision medicine approved in the EU for first-line treatment of people with RET fusion-positive advanced NSCLC Conditional approval is based on results from the phase I/II ARROW study, in which Gavreto led to durable responses in people with RET fusion-positive advanced NSCLC Basel, 19 November 2021 – Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that…
Source: www.roche.comCategories: Hem/Oncs, Latest HeadlinesTweet-
⭐️🚨European Commission approves Pralsetinib for the treatment of adults with RET fusion-positive advanced non-small cell lung cancer 🎯@OncoAlert @RETpositive @RetRenegades #precisionmedicine https://t.co/jEzn045ZWI
-
-
Mashup Score: 6Roche provides update on Tecentriq US indication for PD-L1-positive, metastatic triple-negative breast cancer - 3 year(s) ago
Basel, 27 August 2021 – Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the company has made the decision to voluntarily withdraw the US accelerated approval for Tecentriq® (atezolizumab) in combination with chemotherapy (Abraxane®, albumin-bound paclitaxel; nab-paclitaxel) for the treatment of adults with unresectable locally advanced or metastatic triple-negative breast cancer…
Source: www.roche.comCategories: Latest Headlines, Oncologists2Tweet-
RT @jamecancerdoc: https://t.co/LWDmeA4hlB @OncoAlert @FDAOncology no longer considers it is appropriate to maintain the accelerated approv…
-
RT @jamecancerdoc: https://t.co/LWDmeA4hlB @OncoAlert @FDAOncology no longer considers it is appropriate to maintain the accelerated approv…
-
-
Mashup Score: 2Roche provides update on Tecentriq US indication for PD-L1-positive, metastatic triple-negative breast cancer - 3 year(s) ago
Basel, 27 August 2021 – Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the company has made the decision to voluntarily withdraw the US accelerated approval for Tecentriq® (atezolizumab) in combination with chemotherapy (Abraxane®, albumin-bound paclitaxel; nab-paclitaxel) for the treatment of adults with unresectable locally advanced or metastatic triple-negative breast cancer…
Source: www.roche.comCategories: Hem/Oncs, Latest HeadlinesTweet-
https://t.co/LWDmeA4hlB @OncoAlert @FDAOncology no longer considers it is appropriate to maintain the accelerated approval of atezolizumab in the treatment of #metastatic #TNBC @Roche is withdrawing its indication https://t.co/c7YDdASZ6l
-
-
Mashup Score: 0Roche provides update on Tecentriq US indication for PD-L1-positive, metastatic triple-negative breast cancer - 3 year(s) ago
Basel, 27 August 2021 – Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the company has made the decision to voluntarily withdraw the US accelerated approval for Tecentriq® (atezolizumab) in combination with chemotherapy (Abraxane®, albumin-bound paclitaxel; nab-paclitaxel) for the treatment of adults with unresectable locally advanced or metastatic triple-negative breast cancer…
Source: www.roche.comCategories: Latest Headlines, Oncologists2Tweet-
ROCHE announced that the company has made the decision to voluntarily withdraw the US accelerated approval for Tecentriq in combination with chemotherapy for the treatment of mTNBC. Pembrolizumab is the only IO that remains in the market #BCSM @OncoAlert https://t.co/zpf8zW8yTF
-
-
Mashup Score: 9Roche provides update on Tecentriq US indication for PD-L1-positive, metastatic triple-negative breast cancer - 3 year(s) ago
Basel, 27 August 2021 – Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the company has made the decision to voluntarily withdraw the US accelerated approval for Tecentriq® (atezolizumab) in combination with chemotherapy (Abraxane®, albumin-bound paclitaxel; nab-paclitaxel) for the treatment of adults with unresectable locally advanced or metastatic triple-negative breast cancer…
Source: www.roche.comCategories: Latest Headlines, Oncologists1Tweet-
Atezolizumab FDA indication in 1st line metastatic triple-negative breast cancer will cease due to the treatment landscape change by KEYNOTE-522. Surprised but not surprised. #bcsm https://t.co/0VeFXHEyVD
-
Happening Now! @Roche decided to voluntarily withdraw the US accelerated approval for Atezolizumab in combination w/nab-paclitaxel for PD-L1+ unresec LA/mTNBC 👉This decision only impacts the US #bcsm #ImmunoOnc #Immunotherapy #breastcancer #mustread https://t.co/ryaBwH4oeJ
-
Roche "has made the decision" to withdraw the U.S. accelerated approval for Tecentriq (atezolizumab) in comb. w/ chemo (Abraxane) for people w/ advanced or metastatic #PDL-1+ triple negative breast cancer, @Roche - https://t.co/GkfQlLP5y9 #IO #mbc #TNBC #FDAapprovals
-
FDA has granted a Priority Review for tocilizumab (Actemra) intravenous for the treatment of hospitalised COVID-19 adults receiving systemic corticosteroids and require supplemental O2, mechanical ventilation, or ECMO. https://t.co/b4GSuvsElp https://t.co/oEGskAJVyd